Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom in Pakistani patients with MASH
NCT07249788Phase 4Recruiting
- Sponsor
- Nabiqasim Industries
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Nabiqasim Industries. Started Oct 2025; status: recruiting.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07249788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249788.